Private equity firm Afinum buys majority stake in Swiss biotech evitria

In This List

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises

Blog

Essential IR Insights Newsletter - Summer July-August 2023

Blog

Insight Weekly: Climate law faces hurdles; US borrowing surges; banks revise uninsured deposits

21 Dec, 2018

Author Mark Louie Bonayon
Theme Healthcare & Pharmaceuticals

Private equity firm Afinum Achte Beteiligungsgesellschaft mbH & Co. KG acquired a majority stake in Swiss biotechnology company evitria AG.

Evitria provides custom antibodies to pharmaceutical and biotech companies for research purposes.

Afinum Achte Beteiligungsgesellschaft mbH & Co. KG, advised by Afinum Management GmbH, acts as lead investor and majority owner, and jointly invests with SHS V Medtech Investments GmbH & Co. KG and management into evitria.